NCT05462366

Brief Summary

The investigators aim to collect breast-milk and feces from the participants, and apply culture techniques as well as omics sequencing technology to probe into the microbial and metabolomic signature of the specimens.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Jun 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Jun 2021Dec 2026

Study Start

First participant enrolled

June 22, 2021

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

July 6, 2022

Completed
12 days until next milestone

First Posted

Study publicly available on registry

July 18, 2022

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2026

Expected
Last Updated

July 25, 2023

Status Verified

July 1, 2023

Enrollment Period

3.5 years

First QC Date

July 6, 2022

Last Update Submit

July 22, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Compare the omics differences of the specimens between the experimental and control groups

    Apply 16S amplicon sequencing and shotgun sequencing technology to obtain microbial structure of the specimens. The differences of microbial structure will be compared between the experimental and control groups. Significance among multiple groups was tested using a one-way analysis of variance (ANOVA), followed by the least significant difference (LSD) post hoc test. Groups with different characters denoting a significant difference, while having the same character denotes p-value \> 0.05 in LSD test.

    2021.7.1-2026.12.30

  • Compare the microbial feature differences of the specimens between the experimental and control groups

    Apply traditional culture technologies to validate and obtain human source bacteria.The differences of frequencies of probiotics will be compared between the experimental and control groups. Depending on the distribution of the variables, either the Mann-Whitney test or the unpaired Student's t-test was employed for quantitative variables. The Kruskal-Wallis test for mean values was used to evaluate non-parametric comparisons between participants in all groups. Significance among multiple groups was tested using a one-way analysis of variance (ANOVA), followed by the least significant difference (LSD) post hoc test. Groups with different characters denoting a significant difference, while having the same character denotes p-value \> 0.05 in LSD test.

    2021.7.1-2026.12.30

Secondary Outcomes (1)

  • Compare the health status differences between the experimental and control groups

    2021.7.1-2026.12.30

Study Arms (2)

Mother

healthy mothers

Other: Sample collection

Infant

healthy infants

Other: Sample collection

Interventions

Collect breast-milk and feces from mother-infant-pairs.

InfantMother

Eligibility Criteria

AgeUp to 40 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

This study intends to screen pregnant women in the Obstetrics and Gynecology Center of Zhujiang Hospital, Southern Medical University, and preliminarily recruit subjects that meet the inclusion criteria according to clinical diagnosis and auxiliary examination results. According to the specific conditions of vaginal delivery and post-birth newborns, the final inclusion of healthy pregnant women and newborns will be determined, and a total of 40-50 mother-infant-pairs will be recruited

You may qualify if:

  • healthy pregnant women aged between 20y and 40y.
  • Vaginal birth
  • BMI\<23.5 before pregnancy
  • Infants' birth weight, between 2500g and 4000g.

You may not qualify if:

  • gestational diabetes
  • diagnosis of depressive disorder during pregnancy
  • gestational hypertension
  • diagnosis of other diseases during pregnancy
  • Under probiotics or antibiotic treatment from 3 months prior to pregnancy till 3 months after delivery
  • histrory of smoking and drinking alcohol
  • history of diarrhea from 3 months prior to pregnancy till 3 months after delivery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhujiang Hospital

Guangzhou, Guangdong, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Breastmilk and feces from mother-infant-pairs

MeSH Terms

Conditions

Breast Milk Expression

Interventions

Specimen Handling

Condition Hierarchy (Ancestors)

Breast FeedingFeeding BehaviorBehavior

Intervention Hierarchy (Ancestors)

Clinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Central Study Contacts

Ying Ma, Doctor

CONTACT

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

July 6, 2022

First Posted

July 18, 2022

Study Start

June 22, 2021

Primary Completion

December 30, 2024

Study Completion (Estimated)

December 30, 2026

Last Updated

July 25, 2023

Record last verified: 2023-07

Locations